# A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.

> **NCT07669454** · PHASE3 · RECRUITING · sponsor: **Natureceuticals Sdn Bhd** · enrollment: 250 (estimated)

## Conditions studied

- Fatigue Related to Cancer Treatment
- Colon Cancer

## Interventions

- **DRUG:** Nuvastatic 300
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07669454
- **Lead sponsor:** Natureceuticals Sdn Bhd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-11-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669454, "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*